|
1
|
Nishi H, Toda K, Miyagawa S, Yoshikawa Y,
Fukushima S, Kawamura M, Yoshioka D, Saito T, Ueno T, Kuratani T,
et al: Effects of tolvaptan in the early postoperative stage after
heart valve surgery: Results of the STAR (Study of Tolvaptan for
fluid retention AfteR valve surgery) trial. Surg Today.
45:1542–1551. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kishimoto Y, Nakamura Y, Harada S, Onohara
T, Kishimoto S, Kurashiki T, Fujiwara Y and Nishimura M: Can
Tolvaptan Protect Renal Function in the Early Postoperative Period
of Cardiac Surgery? - Results of a Single-Center Randomized
Controlled Study. Circ J. 82:999–1007. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Felker GM: Loop diuretics in heart
failure. Heart Fail Rev. 17:305–311. 2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Haller C, Salbach P, Katus H and Kübler W:
Refractory oedema in congestive heart failure: A contributory role
of loop diuretics? J Intern Med. 237:211–214. 1995.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Costello-Boerrigter LC, Smith WB,
Boerrigter G, Ouyang J, Zimmer CA, Orlandi C and Burnett JC Jr:
Vasopressin-2-receptor antagonism augments water excretion without
changes in renal hemodynamics or sodium and potassium excretion in
human heart failure. Am J Physiol Renal Physiol. 290:F273–F278.
2006.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Sen J, Chung E and McGill D: Tolvaptan for
Heart Failure in Chronic Kidney Disease Patients: A Systematic
Review and Meta-Analysis. Heart Lung Circ. 27:928–939.
2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Ito H, Mizumoto T, Tempaku H, Fujinaga K,
Sawada Y and Shimpo H: Efficacy of Tolvaptan on Fluid Management
After Cardiovascular Surgery Using Cardiopulmonary Bypass. J
Cardiothorac Vasc Anesth. 30:1471–1478. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Yamada M, Nishi H, Sekiya N, Horikawa K,
Takahashi T and Sawa Y: The efficacy of tolvaptan in the
perioperative management of chronic kidney disease patients
undergoing open-heart surgery. Surg Today. 47:498–505.
2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kido T, Nishi H, Toda K, Ueno T, Kuratani
T, Sakaki M, Takahashi T and Sawa Y: Predictive factors for
responders to tolvaptan in fluid management after cardiovascular
surgery. Gen Thorac Cardiovasc Surg. 65:110–116. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Moher D, Liberati A, Tetzlaff J and Altman
DG: PRISMA Group. Preferred reporting items for systematic reviews
and meta-analyses: The PRISMA statement. PLoS Med.
6(e1000097)2009.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Higgins J and Green S (eds): Cochrane
Handbook for Systemic Reviews of Interventions Version 5.1.0. The
Cochrane Collaboration, 2011. http://www.handbook.cochrane.orgsimplewww.handbook.cochrane.org.
Updated March, 2011.
|
|
12
|
Higgins J, Altman D and Sterne J: Cochrane
Statistical Methods Group and the Cochrane Bias Methods Group.
Chapter 8: Assessing risk of bias in included studies. In: Cochrane
Handbook for Systemic Reviews of Interventions, Version 5.1.0. The
Cochrane Collaboration, 2011. http://www.handbook.cochrane.orgsimplewww.handbook.cochrane.org.
Accessed May 8, 2014.
|
|
13
|
Noguchi K, Tanaka M, Katayama I, Yamabe T,
Yuji D, Oosiro N and Sirouzu M: Efficacy of Tolvaptan in Patients
with Volume Overload after Cardiac Surgery. Heart Surg Forum.
18:E232–E236. 2015.PubMed/NCBI View
Article : Google Scholar
|
|
14
|
Kato TS, Ono S, Kajimoto K, Kuwaki K,
Yamamoto T and Amano A: Early introduction of tolvaptan after
cardiac surgery: A renal sparing strategy in the light of the renal
resistive index measured by ultrasound. J Cardiothorac Surg.
10(143)2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Katayama Y, Ozawa T, Shiono N, Masuhara H,
Fujii T and Watanabe Y: Safety and effectiveness of tolvaptan for
fluid management after pediatric cardiovascular surgery. Gen Thorac
Cardiovasc Surg. 65:622–626. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Matsuyama K, Koizumi N, Nishibe T, Iwasaki
T, Iwahasi T, Toguchi K, Takahashi S, Iwahori A, Maruno K and Ogino
H: Effects of short-term administration of tolvaptan after open
heart surgery. Int J Cardiol. 220:192–195. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Kato TS, Nakamura H, Murata M, Kuroda K,
Suzuki H, Yokoyama Y, Shimada A, Matsushita S, Yamamoto T and Amano
A: The effect of tolvaptan on renal excretion of electrolytes and
urea nitrogen in patients undergoing coronary artery bypass
surgery. BMC Cardiovasc Disord. 16(181)2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Suehiro Y, Hosono M, Shibata T, Sasaki Y,
Hirai H, Nakahira A, Kubota Y, Kaku D and Suehiro S: Efficacy and
Safety Evaluation of Tolvaptan on Management of Fluid Balance after
Cardiovascular Surgery Using Cardiopulmonary Bypass. Osaka City Med
J. 62:111–119. 2016.PubMed/NCBI
|
|
19
|
Woods WG, Forsling ML and Le Quesne LP:
Plasma arginine vasopressin levels and arterial pressure during
open heart surgery. Br J Surg. 76:29–32. 1989.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Jochberger S, Mayr VD, Luckner G, Wenzel
V, Ulmer H, Schmid S, Knotzer H, Pajk W, Hasibeder W, Friesenecker
B, et al: Serum vasopressin concentrations in critically ill
patients. Crit Care Med. 34:293–299. 2006.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Miyazaki T, Fujiki H, Yamamura Y, Nakamura
S and Mori T: Tolvaptan, an orally active vasopressin V(2)-receptor
antagonist - pharmacology and clinical trials. Cardiovasc Drug Rev.
25:1–13. 2007.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Gheorghiade M, Gattis WA, O'Connor CM,
Adams KF Jr, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew
FA, Klapholz M, et al: Acute and Chronic Therapeutic Impact of a
Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF)
Investigators: Effects of tolvaptan, a vasopressin antagonist, in
patients hospitalized with worsening heart failure: A randomized
controlled trial. JAMA. 291:1963–1971. 2004.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Gheorghiade M, Konstam MA, Burnett JC Jr,
Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T,
Ouyang J, et al: Efficacy of Vasopressin Antagonism in Heart
Failure Outcome Study With Tolvaptan (EVEREST) Investigators:
Short-term clinical effects of tolvaptan, an oral vasopressin
antagonist, in patients hospitalized for heart failure: The EVEREST
Clinical Status Trials. JAMA. 297:1332–1343. 2007.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Slight RD, Demosthenous N, Nzewi OC,
Soliman AR, McClelland DBL and Mankad PS: The effect of gain in
total body water on haemoglobin concentration and body weight
following cardiac surgery. Heart Lung Circ. 15:256–260.
2006.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Bellos I, Iliopoulos DC and Perrea DN: The
Role of Tolvaptan Administration After Cardiac Surgery: A
Meta-Analysis. J Cardiothorac Vasc Anesth. 33:2170–2179.
2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Crestanello JA, Phillips G, Firstenberg
MS, Sai-Sudhakar C, Sirak J, Higgins R and Abraham WT:
Postoperative hyponatremia predicts an increase in mortality and
in-hospital complications after cardiac surgery. J Am Coll Surg.
216:1135–43, 1143.e1. 2013.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Matsuzaki M, Hori M, Izumi T and Fukunami
M: Tolvaptan Investigators. Efficacy and safety of tolvaptan in
heart failure patients with volume overload despite the standard
treatment with conventional diuretics: A phase III, randomized,
double-blind, placebo-controlled study (QUEST study). Cardiovasc
Drugs Ther. 25 (Suppl 1):S33–S45. 2011.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Peretto G, Durante A, Limite LR and
Cianflone D: Postoperative arrhythmias after cardiac surgery:
Incidence, risk factors, and therapeutic management. Cardiol Res
Pract. 2014(615987)2014.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Lazzarini V, Bettari L, Bugatti S,
Carubelli V, Lombardi C, Metra M and Dei Cas L: Can we prevent or
treat renal dysfunction in acute heart failure? Heart Fail Rev.
17:291–303. 2012.
|
|
30
|
Tominaga N, Kida K, Matsumoto N, Akashi
YJ, Miyake F, Kimura K and Shibagaki Y: Safety of add-on tolvaptan
in patients with furosemide-resistant congestive heart failure
complicated by advanced chronic kidney disease: A sub-analysis of a
pharmacokinetics/ pharmacodynamics study. Clin Nephrol. 84:29–38.
2015.PubMed/NCBI View
Article : Google Scholar
|
|
31
|
Shirakabe A, Hata N, Yamamoto M, Kobayashi
N, Shinada T, Tomita K, Tsurumi M, Matsushita M, Okazaki H,
Yamamoto Y, et al: Immediate administration of tolvaptan prevents
the exacerbation of acute kidney injury and improves the mid-term
prognosis of patients with severely decompensated acute heart
failure. Circ J. 78:911–921. 2014.PubMed/NCBI View Article : Google Scholar
|
